No Data
No Data
Sector Update: Health Care
Emergent BioSolutions Wins $50 Million Contract Option for Cyfendus; Shares Rise
Express News | Emergent BioSolutions Inc - Cyfendus Vaccine Deliveries Expected to Complete by April 2025
Express News | Emergent BioSolutions Receives $50 Million Contract Option From Barda to Procure Doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted)
Investors Don't See Light At End Of Emergent BioSolutions Inc.'s (NYSE:EBS) Tunnel And Push Stock Down 26%
Emergent BioSolutions Inc.'s (NYSE:EBS) Institutional Investors Lost 11% Last Week but Have Benefitted From Longer-term Gains